Below is a recording of the session titled: Infrastructure considerations: Outlook for blood-based testing as part of the Goldman Sachs Alzheimer’s Disease Day, held on October 3, 2023 in New York City. Dr. Joel Braunstein, CEO of C₂N Diagnostics, provides remarks on the outlook for blood-based testing for Alzheimer’s disease. Matt Sykes, Vice President of Goldman Sachs serves as moderator.
Unlock the Session below.
Goldman Sachs Alzheimer’s Disease Day — Infrastructure considerations: Outlook for blood-based testing
Previous
Previous
Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer’s Disease
Next
Next